Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with renal cell carcinoma (RCC).
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.
Category
- Glioma
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Event date August 30, 2024
NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer
Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.
Category
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Event date September 4, 2024
NCCN Pharmacy Updates: Updates in the Treatment of Kidney Cancer
The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.
Category
- Kidney Cancer
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Event date September 27, 2024
NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Category
- Gastric/Esophageal Cancer
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Event date October 21, 2024
NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
Category
- Breast Cancer
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Event date October 29, 2024
NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer
This webinar will provide a summary of the newest chemoimmunotherapy options in advanced NSCLC and the toxicities associated with these combination regimens.
Category
- Lung Cancers
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Event date November 6, 2024